Evaluation of 4‐bp insertion/deletion polymorphism within the 3′UTR of SGSM3 in bladder cancer using mismatch PCR‐RFLP method: A preliminary report

Abstract

The small G protein signaling modulator 3 (SGSM3) has been shown to be associated with small G-protein-coupled receptor signaling. There is little data regarding the impact of SGSM3 polymorphisms on cancer risk. In the present study, we aimed to evaluate the impact of 4-bp insertion/deletion (rs56228771) polymorphism in the 3'UTR of SGSM3 and susceptibility to bladder cancer in a sample of the Iranian population. This case-control study included 143 pathologically confirmed bladder cancer patients and 144 healthy subjects. The SGSM3 4-bp ins/del (rs56228771) variant was determined by mismatch PCR-RFLP. The findings showed that ins/del genotype and ins allele of SGSM3 4-bp ins/del polymorphism significantly increased the risk of bladder cancer (OR = 3.11, 95%CI = 1.70-5.71, P < 0.0001 and OR = 2.11, 95%CI = 1.27-3.52, P = 0.004, respectively). Our findings support an association between 4-bp ins/del polymorphism in the 3'UTR of SGSM3 and the risk of bladder cancer in an Iranian population. Additional studies with larger sample sizes and diverse ethnicities are warranted to establish if such an association exists in general.

Association between an indel polymorphism within the distal promoter of EGLN2 and cancer risk: An updated meta‐analysis

“…Thereinto a significant association existed in lung cancer, gastric cancer, and colorectal cancer, which was consistent with the results of Zhu's study in 2012 (Che et al, ; Li et al, ; Wang et al, ; Zhu et al, , ). However, there was also an inconsistent result in breast cancer (Hashemi, Danesh, et al, ). Hashemi et al examined the possible association between the rs10680577 polymorphism and the risk of breast cancer in a southeast Iranian population, and did not observe significant differences in the genotype and allele frequencies between breast cancer patients and controls.…”

“…So we speculated that genetic polymorphisms affecting EGLN2 expression could confer an individual's susceptibility to cancer. Interestingly, several studies have focused on the association between a functional polymorphism within EGLN2 and the risk of cancers, including breast cancer, lung cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma (Che et al, 2014;Hashemi, Danesh, et al, 2018;Li et al, 2017;Wang, Zhang, Zhou, Chen, & Yu, 2014;Zhu, Luo, & Li, 2019;Zhu et al, 2012). This functional polymorphism is a 4-bp insertion/deletion (indel) polymorphism (rs10680577) within the distal promoter of EGLN2, which can affect the expression of EGLN2 (Zhu et al, 2012).…”

Genetic and molecular biology of bladder cancer among Iranian patients

“…The small G‐protein signaling modulator 3 ( SGSM3 ) (OMIM: 610440) is a GTPase involving in regulation of G‐protein and Ras signaling (Yang, Sasaki, Minoshima, & Shimizu, 2007). It has been shown that the 4‐bp ins/del genotype and ins allele of SGSM3 significantly increased the BC susceptibility among a subpopulation of Iranian patients (Hashemi et al, 2018). Sphingosine 1‐phosphate ( S1P ) (OMIM: 601965) is a bioactive lysosphingolipid mediator that binds to S1PRn (a G‐protein–coupled receptor) to regulate MAPKs .…”

Small G protein signaling modulator 3 (SGSM3) knockdown attenuates apoptosis and cardiogenic differentiation in rat mesenchymal stem cells exposed to hypoxia

“…SGSM3 increases Cx43 turnover by accelerating the internalization of Cx43 from the plasma membrane [37]. On the other hand, several studies have shown that SGSM3 is associated with the risk of some cancers, including liver, breast, colorectal and bladder cancers [38][39][40][41].…”